Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-118 12-week extension study in opioid-induced constipation
2011-002187-24Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naloxegol in opioid-induced constipation (OIC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Long-term safety and tolerability. Started Aug 2011; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2011-002187-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002187-24.